Biogaia Ab Class B · OMXSTO:BIOG_B
Biogaia Ab Class B — Q2 2025 Earnings Presentation
16 slides from Biogaia Ab Class B's earnings presentation, Jul 18, 2025
Slide 1: Q2 2025 Results Telephone Conference
Q2 2025 RESULTS Telephone Conference 18 July 2025 Theresa Agnew, CEO Alexander Kotsinas, CFO
Slide 2: Executive Summary Q2 2025
Executive summary Executive summary Sales breakdown Sales breakdown Financials Financials Concluding remarks remarks Concluding Executive Summary Q2 2025 • Sales were 405 MSEK (+5%) due to higher sales in Americas and APAC, growth of 13.2% excluding currency effects • Sales in EMEA decreased by 1%,
Slide 3: Launches
Executive summary Executive summary Sales breakdown Sales breakdown Financials Financials Concluding remarks remarks Concluding Launches Distributor Country Product Pemix Malta BioGaia Gastrus Abbott Jordan BioGaia Protectis drops BioGaia Sweden BioGaia Gastrus Pure Action Ewopharma Poland BioGaia G
Slide 4: Key Events
Executive summary Executive summary Sales breakdown Sales breakdown Financials Financials Concluding remarks remarks Concluding Key Events • May 7: BioGaia announced that it is expanding its global footprint by establishing direct sales in the Netherlands initially through an online approach • May 3
Slide 5: Sales per Segment
Executive summary Executive summary Sales breakdown Sales breakdown Financials Financials Concluding remarks remarks Concluding Sales per Segment Sales per Segment Q2 2025 1% MSEK Q2 2025 Q2 2024 Change YTD 2025 YTD 2024 Change 22% Pediatrics 310 305 2% 580 597 -3% Adult Health 90 78 15% 184 153 20%
Slide 6: Sales per Region
Executive summary Executive summary Sales breakdown Sales breakdown Financials Financials Concluding remarks remarks Concluding Sales per Region Sales per Region Q2 2025 MSEK Q2 2025 Q2 2024 Change YTD 2025 YTD 2024 Change EMEA 137 137 -1% 260 299 -13% 39% 34% APAC 112 97 15% 181 183 -1% Americas 15
Slide 7: Financials
Alexander Kotsinas, CFO Financials 7
Slide 8: Key Financials
Executive summary Executive summary Sales breakdown Sales breakdown Financials Financials Concluding remarks remarks Concluding Key Financials Sales (MSEK) Gross profit (MSEK) EBIT (MSEK) +3% +5% 294 284 405 384 -20% 135 108 74% 73% 35% 27% Q2 2024 Q2 2025 Q2 2024 Q2 2025 Q2 2024 Q2 2025 8
Slide 9: Sales Bridge
Executive summary Executive summary Sales breakdown Sales breakdown Financials Financials Concluding remarks remarks Concluding Sales Bridge +5% -30 405 384 51 Q2 2024 Organic Currency Q2 2025 growth effect Change 13% -8% 9
Slide 10: Gross Margin per Segment
Executive summary Executive summary Sales breakdown Sales breakdown Financials Financials Concluding remarks remarks Concluding Gross Margin per Segment Gross margin Q2 2025 Q2 2024 YTD 2025 YTD 2024 Pediatrics 74% 77% 75% 76% Adult Health 66% 61% 66% 59% Total 73% 74% 73% 73% • Adult Health: gross
Slide 11: Operating Expenses (OPEX)
Executive summary Executive summary Sales breakdown Sales breakdown Financials Financials Concluding remarks remarks Concluding Operating Expenses (OPEX) MSEK Q2 2025 Q2 2024 Change YTD 2025 YTD 2024 Change Sales and Marketing -138 -110 25% -251 -206 22% Research and Development -30 -27 13% -53 -52
Slide 12: Profit and Loss Statement
Executive summary Executive summary Sales breakdown Sales breakdown Financials Financials Concluding remarks remarks Concluding Profit and Loss Statement MSEK Q2 2025 Q2 2024 Change YTD 2025 YTD 2024 Change Sales 405 384 5% 771 754 2% Gross profit 294 284 3% 562 550 2% Percentage of revenue 73% 74%
Slide 13: Cashflow
Executive summary Executive summary Sales breakdown Sales breakdown Financials Financials Concluding remarks remarks Concluding Cashflow MSEK Q2 2025 Q2 2024 Change YTD 2025 YTD 2024 Change Cash flow from operating activities before 91 124 -26% 172 246 -30% changes in net working capital Changes in
Slide 14: Concluding Remarks
Executive summary Executive summary Sales breakdown Sales breakdown Financials Financials Concluding remarks remarks Concluding Concluding Remarks Q2 2025 • Strong sales momentum returned in the second quarter, supported by high demand in key markets, especially in APAC and North America • Sales for
Slide 15: Q&A
Q&A
Slide 16: BioGaia
BioGaia.